Diagnostyka S.A.
157.70
PLN
+2.60
(+1.68%)
ISIN
PLDGNST00012
Return %
Stock
S&P 500
1Y
-17.84
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
PLN
•
in mil. unless spec.Working Capital
PLN
•
in mil. unless spec.Growth Rates
PLN
•
in mil. unless spec.Quarterly Revenue
PLN
•
in mil. unless spec.Quarterly Earnings Per Share
PLN
•
in mil. unless spec.Quarterly Dividends Per Share
PLN
•
in mil. unless spec.Company Description
- CEO
- Jakub Swadzba
- Full Time Employees
- 7,635
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Kraków Poland
- IPO Date
- Feb 7, 2025
- Website
- grupadiagnostyka.pl
- Similar Companies
- Business
- Diagnostyka S.A. is a Poland-based healthcare company that provides comprehensive medical laboratory diagnostics and diagnostic imaging services. Founded in 1998 and headquartered in Kraków, Poland, the company operates the largest nationwide diagnostic network in Poland, comprising more than 150 medical laboratories and approximately 1,300 specimen collection points. The company serves both retail individual patients and institutional B2B clients, including public and private hospitals, outpatient medical centers, specialty clinics, corporate employer health programs, universities, and clinical research organizations. The company operates through two main business segments: Medical Laboratory Diagnostic Services and Diagnostic Imaging Services. Its laboratory portfolio encompasses over 4,000 individual diagnostic tests and specialized diagnostic profiles, including routine clinical biochemistry; hematology, coagulation, and urinalysis; microbiology, mycology, and serology; immunology and allergology; molecular diagnostics, cytogenetics, and Next-Generation Sequencing (NGS) genetic testing; oncology biomarkers, histopathology, and cervical cytology; toxicology and therapeutic drug monitoring; as well as mobile home-sampling services and digital patient result delivery platforms. Through its diagnostic imaging division, the company provides magnetic resonance imaging (MRI); computed tomography (CT); diagnostic ultrasound (USG); digital X-ray (RTG); mammography; bone densitometry; mobile medical scanning units; and specialized digital teleradiology reading services operated through TeleDiagnostyka and Teleradiologia24. Additionally, the company offers subscription-based personalized health and wellness screening solutions under its Longevity+ preventive medicine brand. In recent developments, Diagnostyka S.A. completed its initial public offering on the Main Market of the Warsaw Stock Exchange under the ticker DIA in February 2025, representing an offering value of approximately PLN 1.7 billion. The group has actively accelerated its strategic diversification by expanding its footprint in advanced imaging centers and digital pathology workflows. Demonstrating a long-term buy-and-build consolidation strategy with more than 120 historical laboratory acquisitions, the company has transitioned toward highly selective acquisitions in specialized diagnostics and imaging, while completing a strategic investment in healthcare platform AidPort to facilitate digital service delivery and future international market expansion. Diagnostyka S.A. conducts its nationwide operations directly and through a corporate network of more than 20 operating subsidiaries.